Key takeaways
- GLOW is a seller name for one vial that lists GHK-Cu, BPC-157 and TB-500; “Wolverine” is a seller name for one that lists BPC-157 and TB-500. The difference is GHK-Cu.
- We found no published study or registered trial of either mix as sold, and none comparing them (PubMed and ClinicalTrials.gov, 21 Nov 2026).
- GHK-Cu’s own record, in the studies cited here, is cell and animal work plus one small randomised skin study in people; none of it transfers to a mixed vial.
- Regulators and WADA set status one compound at a time, and none of the status documents we read names either mix.
- A lab report for a vial that lists three peptides has three identities to confirm; for two peptides, two.
01GLOW and “Wolverine” side by side
The same questions, asked of two names for pre-mixed vials. Dated 21 November 2026.
| Question | GLOW | “Wolverine” |
|---|---|---|
| What the name refers to | A seller name for one vial that mixes three peptides | A seller name for one vial that mixes two peptides |
| Listed components | GHK-Cu, BPC-157, TB-500 | BPC-157, TB-500 |
| The component that differs | GHK-Cu is listed | GHK-Cu is not listed |
| Studied as a mix | No study found, in any species | No study of a vial sold under the name. Three papers we found gave BPC-157 with TB-500 or thymosin β4: a 2026 rat study and two uncontrolled human reports |
| Compared with the other | No study found | No study found |
| Evidence tier of the studies cited here, component by component | GHK-Cu: one small randomised skin study in people (T1), plus animal (T3) and cell (T4) studies. BPC-157: small human studies (T2) and animal studies (T3). TB-500: animal and cell studies (T3, T4) | BPC-157 and TB-500 as on the left |
| United States | Drugs@FDA lists no medicine containing any of the three. FDA’s list of substances nominated for compounding (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, under evaluation. HHS’s October 2026 draft policy, which “is not binding”, names BPC-157 and TB-500, not GHK-Cu, and covers single-ingredient products only | BPC-157 and TB-500 as on the left |
| Australia | The TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” BPC-157 and TB-500 are in Schedule 4 and Appendix D of the Poisons Standard October 2026. GHK-Cu has no entry by name, and the standard has group entries for copper compounds; we draw no scheduling conclusion of our own | BPC-157 and TB-500 as on the left, with the same TGA sentence |
| United Kingdom | The emc database returned no results for GHK, BPC-157 or TB-500 (21 Nov 2026); it is not the full UK register | The same for BPC-157 and TB-500 |
| Sport (WADA 2026 and 2027 Lists) | BPC-157 (class S0) and TB-500 (class S2.3) are named, prohibited at all times. GHK-Cu is not named, and WADA says a peptide not specifically named “may still be prohibited” | BPC-157 and TB-500 as on the left |
| Identities a lab report has to confirm | Three | Two |
If you searched “glow vs wolverine peptide”, the two names differ by one listed component, and what is known about that component is not known about either mix. To see what each name covers: what is the “GLOW peptide”? and what is the “Wolverine peptide”?
02What does GHK-Cu add to the listed components?
One extra molecule on one side. The drawings show which molecules are listed, not how much of each.
GHK-Cu: the extra molecule
Glycyl-L-histidyl-L-lysine, a peptide of three amino acids, holding a copper(II) ion. The earliest papers we found on GHK in PubMed date from 1973.
GLOW: three listed names
GHK-Cu with BPC-157 and TB-500 in one vial. No regulator or peer-reviewed source defines the mix or says how much of each it holds.
Wolverine: two listed names
BPC-157 and TB-500 in one vial. Again no source defines the mix or the amounts, and GHK-Cu is not listed.
What is known about GHK-Cu is not known about either mix. Evidence attaches to what was studied, never to a name for a mix: peptide blends: one vial, no shared evidence.
03What has GHK-Cu been studied in, and has any study covered the pair or the trio?
GHK-Cu’s own record, design and measures only. None of these studies gave GHK-Cu with another peptide.
| Study | Model and n | What was measured | Tier |
|---|---|---|---|
| Miller et al., 2006 | People: a randomised comparison of skin-care regimens with or without GHK-Cu after laser resurfacing around the mouth; 13 completed | Redness, by software and blinded evaluators; wrinkles and skin quality at 12 weeks; a patient questionnaire | T1, small |
| Maquart et al., 1993 | Rats with implanted wound chambers; n not given in the abstract | Dry weight, protein, collagen and DNA content of the chamber tissue | T3 |
| Maquart et al., 1988 | Fibroblasts in culture | Collagen production by the cells | T4 |
An animal or cell result is not evidence of an effect in people, and material sold online is not the product these studies tested. GHK-Cu’s guide grades its human evidence “Early human”: the GHK-Cu guide.
What the pair has, and the trio lacks. Three papers we found gave BPC-157 with TB-500 or thymosin β4: a 2026 study in rats after Achilles tendon repair, a 2026 report of three patients who also received other agents, and a 2021 chart review in which four patients received BPC-157 with thymosin β4; neither human report had a control group. We found no study that added GHK-Cu to them. On 21 November 2026 PubMed returned 7 papers naming GHK-Cu, BPC-157 and TB-500 or thymosin β4 together; by publication type and title each is a review, commentary or letter. ClinicalTrials.gov lists no trial that gives two or more of the three together.
04Where do the three components stand with regulators and in sport?
Component by component. None of the status documents we read names either mix.
- Sep 2023FDA Category 2
BPC-157 and TB-500 enter FDA’s list of compounding substances that may present significant safety risks.
- 22 Apr 2026Out of Category 2
HHS records that neither the placement nor the removal changed the status of the two under section 503A.
- 14 May 2026GHK-Cu under evaluation
FDA’s updated list places GHK-Cu, for certain routes of administration only, in Category 1. FDA says it intends to consult its compounding advisory committee before the end of February 2027.
- 1 Oct 2026Poisons Standard October 2026 in force
Australia’s current standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D. We found no entry by name for GHK-Cu.
- 30 Oct 2026HHS draft policy published
It names six peptides, including BPC-157 and TB-500, not GHK-Cu, and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice calls it a draft that “is not binding”.
- 1 Jan 2027WADA 2027 List takes effect
BPC-157 (class S0) and TB-500 (class S2.3) remain named. GHK-Cu is not named, and WADA says a peptide not specifically named “may still be prohibited”.
Each component, country by country: BPC-157, TB-500 and GHK-Cu. Sport: peptides and anti-doping.
05What we don’t know, and what would have to be studied
There is no measurement on which to rank one name against the other. These are the studies that would be needed.
Whether the peptides stay intact together in one vial, and for how long, for two peptides and for three. We found none in PubMed (21 Nov 2026).
The same model and measures, with a group for each peptide alone, a group for BPC-157 with TB-500, and a group for all three.
A direct comparison of the pair with the trio, in which GHK-Cu is the single change. We found none, published or registered.
Only that lot’s lab report can show it: two identities and two amounts for a two-peptide vial, three of each for a three-peptide vial.
How to read those lines on a report: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.